Who are Silodosin capsules Control Group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doxazosin mysylate GITS, Midodrine + pyridostigmine, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, Doxazosin (drug), Norepinephrine (Levophed), Bupivacaine-adrenaline.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/silodosin-capsules-control-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Silodosin capsules Control Group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Silodosin capsules Control Group (Silodosin capsules Control Group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Urology.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Silodosin capsules Control Group (Silodosin capsules Control Group) — Shanghai Huilun Pharmaceutical Co., Ltd.. Silodosin is an alpha-1 adrenergic receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Silodosin capsules Control Group TARGET	Silodosin capsules Control Group	Shanghai Huilun Pharmaceutical Co., Ltd.	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Doxazosin mysylate GITS	Doxazosin mysylate GITS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
Doxazosin (drug)	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

Brian J Lipworth · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
Hospital Authority, Hong Kong · 1 drug in this class
Japan Heart Foundation · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
San Francisco Veterans Affairs Medical Center · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Silodosin capsules Control Group — Competitive Intelligence Brief. https://druglandscape.com/ci/silodosin-capsules-control-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing